Gastrovigilance: A Close Watch on Gastrointestinal and Hepatic Disorders- An Indian Perspective
Main Article Content
Abstract
Gastrointestinal and hepatic disorders account for about 25% of consultations among general practitioners in India. Errors in clinical judgement and hesitancy in recommending necessary tests owing to lack of health insurance could result in delayed diagnosis and increased patient morbidity and mortality. Clinicians should thus be well equipped with effective strategies for skilful diagnosis and in a position to weigh the benefit-risk-ratio of recommending pertinent and disregarding less useful diagnostic tests. 'Gastrovigilance' includes disease-specific training for recognising risk factors, algorithms and referral pathways. This narrative review focuses on the common challenges or errors in managing these conditions in Indian clinical practice and their proposed solutions. Literature searches were performed using PubMed/MEDLINE and Google Scholar following the shortlisted gastrointestinal conditions. Based on the published literature and expertise of the senior gastroenterologists, improving disease-specific knowledge can enhance rates of correct diagnosis. Improved screening and patient education can reduce the risk of presentation at advanced stages and consequently improve prognosis. Another significant contributory factor is the patient-physician interaction which affects every stage of the disease management and methods to improve it, therefore vital in improving gastrointestinal and hepatic disease conditions. The most important means of improving gastrovigilance is optimising knowledge access in primary care. This shall improve diagnostic accuracy and reduce the burden of misdiagnosis. In the current narrative review, we have tried to elucidate the concept of gastrovigilance for gastrointestinal and hepatic conditions and substantiate it with published evidence.
Keywords:
Inflammatory bowel disease, Gastroesophageal Reflux Disease, Irritable bowel syndrome, Constipation, Gastrointestinal cancer
Article Details
How to Cite
CHOUDHURI, Dr. Gourdas et al.
Gastrovigilance: A Close Watch on Gastrointestinal and Hepatic Disorders- An Indian Perspective.
Medical Research Archives, [S.l.], v. 11, n. 8, aug. 2023.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/4191>. Date accessed: 13 may 2024.
doi: https://doi.org/10.18103/mra.v11i8.4191.
Section
Research Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Gikas A, Triantafillidis J. The role of primary care physicians in early diagnosis and treatment of chronic gastrointestinal diseases. Int J Gen Med. 2014 Mar 13;7:159-173. doi:10.2147/ijgm.s58888
2. Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD. Hepatology. 2020;72:1605-1616. doi: 10.1002/hep.31173.
3. Shah D, Makharia GK, Ghoshal UC, Varma S, Ahuja V, Hutfless S. Burden of gastrointestinal and liver diseases in India, 1990-2016. Indian J Gastroenterol. 2018;37:439-445. doi: 10.1007/s12664-018-0892-3.
4. PAHO. The burden of digestive diseases in the Region of the Americas, 2000-2019. Pan American Health Organization. 2021. Available at https://www.paho.org/en/noncommunicable-diseases-and-mental-health/noncommunicable-diseases-and-mental-health-data-38 Last accessed 03-Oct-2022
5. Jones R. Primary care research and clinical practice: gastroenterology. Postgrad Med J. 2008;84:454-458.
6. Salvi S, Apte K, Madas S, Barne M, Chhowala S, Sethi T, et al. Symptoms and medical conditions in 204 912 patients visiting primary health-care practitioners in India: a 1-day point prevalence study (the POSEIDON study). Lancet Glob Health. 2015;3:e776-784. doi: 10.1016/S2214-109X(15)00152-7.
7. Committee on Diagnostic Error in Health Care; Board on Health Care Services; Institute of Medicine; The National Academies of Sciences, Engineering, and Medicine; Balogh EP, Miller BT, Ball JR, editors. Improving Diagnosis in Health Care. Washington (DC): National Academies Press (US); 2015 Dec 29. 3, Overview of Diagnostic Error in Health Care. Available at: https://www.ncbi.nlm.nih.gov/books/NBK338594/ Last accessed 03-Oct-2022
8. Kostopoulou O, Delaney BC, Munro CW. Diagnostic difficulty and error in primary care--a systematic review. Fam Pract. 2008;25:400-413.
9. Harada T, Watari T, Watanuki S, Hiroshige J, Kushiro S, Miyagami T, et al. Diagnostic error rates and associated factors for lower gastrointestinal perforation. Sci Rep. 2022;12:1028. doi: 10.1038/s41598-021-04762-y.
10. Sriram S, Khan MM. Effect of health insurance program for the poor on out-of-pocket inpatient care cost in India: evidence from a nationally representative cross-sectional survey. BMC Health Serv Res. 2020;20(1):839. doi:10.1186/s12913-020-05692-7
11. Diagnostic Errors: Technical Series on Safer Primary Care. Geneva: World Health Organization; 2016. Licence: CC BY-NC-SA 3.0 IGO. Accessed at https://apps.who.int/iris/bitstream/handle/10665/252410/9789241511636-eng.pdf on 03-Oct-2022
12. Norström F, Lindholm L, Sandström O, Nordyke K, Ivarsson A. Delay to celiac disease diagnosis and its implications for health-related quality of life. BMC Gastroenterol. 2011;11:118. doi:10.1186/1471-230X-11-118
13. Mehta S. GI cancers may masquerade as digestive disorders: Times of India; 2019 [Available from: https://timesofindia.indiatimes.com/city/visakhapatnam/gi-cancers-may-masquerade-as-digestive-disorders-docs/articleshow/69528231.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst. 03-Oct-2022
14. Vaezi MF. Atypical manifestations of gastroesophageal reflux disease. MedGenMed. 2005;7:25.
15. Fujiwara Y, Arakawa T. Overlap in patients with dyspepsia/functional dyspepsia. J Neurogastroenterol Motil. 2014;20:447-457. doi:10.5056/jnm14080.
16. Norström F, Lindholm L, Sandström O, Nordyke K, Ivarsson A. Delay to celiac disease diagnosis and its implications for health-related quality of life. BMC Gastroenterol. 2011;11:118. doi:10.1186/1471-230X-11-118
17. Timmermans WM, van Laar JA, van Hagen PM, van Zelm MC. Immunopathogenesis of granulomas in chronic autoinflammatory diseases. Clin Transl Immunology. 2016;5:e118. doi:10.1038/cti.2016.75
18. Sathoo S, Nachiappan DS, Sureshkumar S, Anandhi A. A qualitative exploratory study of delay in the presentation of gastrointestinal cancer. J Family Med Prim Care. 2021;10):278-282. doi:10.4103/jfmpc.jfmpc_1283_20
19. Bhatia SJ, Makharia GK, Abraham P, et al. Indian consensus on gastroesophageal reflux disease in adults: A position statement of the Indian Society of Gastroenterology. Indian J Gastroenterol. 2019;38:411-440. doi:10.1007/s12664-019-00979-y
20. Rai S, Kulkarni A, Ghoshal UC. Prevalence and risk factors for gastroesophageal reflux disease in the Indian population: A meta-analysis and meta-regression study. Indian J Gastroenterol. 2021;40:209-219. doi: 10.1007/s12664-020-01104-0.
21. Sandhu DS, Fass R. Current Trends in the Management of Gastroesophageal Reflux Disease. Gut Liver. 2018;12:7-16. doi: 10.5009/gnl16615.
22. Smith J, Woodcock A, Houghton L. New developments in reflux-associated cough. Lung. 2010;188 Suppl 1:S81-S86. doi:10.1007/s00408-009-9210-2.
23. Woodcock A, Young EC, Smith JA. New insights in cough. Br Med Bull. 2010;96:61-73. doi:10.1093/bmb/ldq034
24. Bhatia SJ, Reddy DN, Ghoshal UC, Jayanthi V, Abraham P, Choudhuri G, et al. Epidemiology and symptom profile of gastroesophageal reflux in the Indian population: report of the Indian Society of Gastroenterology Task Force. Indian J Gastroenterol. 2011;30:118-127. doi:10.1007/s12664-011-0112-x.
25. Smith JA, Decalmer S, Kelsall A, McGuinness K, Jones H, Galloway S, et al. Acoustic cough-reflux associations in chronic cough: potential triggers and mechanisms. Gastroenterology. 2010;139:754-762. doi:10.1053/j.gastro.2010.06.050.
26. Jain M. Evaluation of noncardiac chest pain in Indian setting--can we reduce the investigation burden?. Indian J Gastroenterol. 2015;34:266-267. doi:10.1007/s12664-014-0527-2
27. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308-329. doi:10.1038/ajg.2012.444.
28. Kahrilas PJ, Smith JA, Dicpinigaitis PV. A causal relationship between cough and gastroesophageal reflux disease (GERD) has been established: a pro/con debate. Lung. 2014;192:39-46. doi:10.1007/s00408-013-9528-7.
29. Pore R, Biswas S, Das S. Prevailing Practices for the Management of Dry Cough in India: A Questionnaire Based Survey. J Assoc Physicians India. 2016;64:48-54.
30. Bhatia S, Pareek KK, Kumar A, Upadhyay R, Tiwaskar M, Jain A, et al. API-ISG Consensus Guidelines for Management of Gastrooesophageal Reflux Disease. J Assoc Physicians India. 2020;68:69-80.
31. Fass R, Ofman JJ. Gastroesophageal reflux disease--should we adopt a new conceptual framework? Am J Gastroenterol. 2002;97:1901-1909. doi:10.1111/j.1572-0241.2002.05912.x
32. Jung DH, Park H. Is Gastroesophageal Reflux Disease and Achalasia Coincident or Not? J Neurogastroenterol Motil. 2017;23:5-8. doi: 10.5056/jnm16121.
33. Kessing BF, Bredenoord AJ, Smout AJ. Erroneous diagnosis of gastroesophageal reflux disease in achalasia. Clin Gastroenterol Hepatol. 2011;9:1020-1024. doi:10.1016/j.cgh.2011.04.022
34. Fallone CA, Guyatt GH, Armstrong D, et al. Do physicians correctly assess patient symptom severity in gastro-oesophageal reflux disease?. Aliment Pharmacol Ther. 2004;20:1161-1169. doi:10.1111/j.1365-2036.2004.02257.x.
35. McColl E, Junghard O, Wiklund I, Revicki DA. Assessing symptoms in gastroesophageal reflux disease: how well do clinicians' assessments agree with those of their patients?. Am J Gastroenterol. 2005;100:11-18. doi:10.1111/j.1572-0241.2005.40945.x
36. Flook NW, Wiklund I. Accounting for the effect of GERD symptoms on patients' health-related quality of life: supporting optimal disease management by primary care physicians. Int J Clin Pract. 2007;61:2071-2078. doi:10.1111/j.1742-1241.2007.01586.x
37. Ponce J, Garrigues V, Agréus L, Tabaglio E, Gschwantler M, Guallar E, et al. Structured management strategy based on the Gastro-oesophageal Reflux Disease (GERD) Questionnaire (GerdQ) vs. usual primary care for GERD: pooled analysis of five cluster-randomised European studies. Int J Clin Pract. 2012;66:897-905. doi:10.1111/j.1742-1241.2012.02992.x
38. Savarino V, Dulbecco P, de Bortoli N, Ottonello A, Savarino E. The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. Eur J Intern Med. 2017;37:19-24. doi:10.1016/j.ejim.2016.10.007
39. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ; American Gastroenterological Association. American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology. 2011;140:e18-e13. doi:10.1053/j.gastro.2011.01.031.
40. Johnson DA, Katz PO, Armstrong D, Cohen H, Delaney BC, Howden CW, et al. The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus. Drugs. 2017;77:547-561. doi:10.1007/s40265-017-0712-6.
41. Scarpignato C, Gatta L, Zullo A, Blandizzi C; SIF-AIGO-FIMMG Group; Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14:179. doi:10.1186/s12916-016-0718-z
42. Moayyedi P, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG Clinical Guideline: Management of Dyspepsia. Am J Gastroenterol. 2017;112:988-1013. doi: 10.1038/ajg.2017.154.
43. Barberio B, Mahadeva S, Black CJ, Savarino EV, Ford AC. Systematic review with meta-analysis: global prevalence of uninvestigated dyspepsia according to the Rome criteria. Aliment Pharmacol Ther. 2020;52:762-773. doi: 10.1111/apt.16006.
44. Mahadeva S, Goh KL. Epidemiology of functional dyspepsia: a global perspective. World J Gastroenterol. 2006;12:2661-2666.
45. Eusebi LH, Ratnakumaran R, Bazzoli F, Ford AC. Prevalence of Dyspepsia in Individuals With Gastroesophageal Reflux-Type Symptoms in the Community: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018;16:39-48.e1. doi:10.1016/j.cgh.2017.07.041.
46. Nasseri-Moghaddam S, Mousavian AH, Kasaeian A, Kanno T, Yuan Y, Ford AC, et al. What is the Prevalence of Clinically Significant Endoscopic Findings in Subjects With Dyspepsia? Updated Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022;S1542-3565(22)00594-8. doi:10.1016/j.cgh.2022.05.041.
47. Plummer M, Franceschi S, Vignat J, Forman D, de Martel C. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer. 2015;136:487-490. doi:10.1002/ijc.28999
48. Vakil N. Dyspepsia, peptic ulcer, and H. pylori: a remembrance of things past. Am J Gastroenterol. 2010;105:572-574. doi:10.1038/ajg.2009.709
49. Wu Y, Su T, Zhou X, Lu N, Li Z, Du Y. Awareness and attitudes regarding Helicobacter pylori infection in Chinese physicians and public population: A national cross-sectional survey. Helicobacter. 2020;25:e12705. doi:10.1111/hel.12705.
50. Mansour Ghanaei1 F, Joukar F, Soati F, Gharib S. Knowledge and Practice of General Practitioners and Internists about Helicobacter pylori infection in Guilan, Iran. Middle East J Dig Dis. 2011;3:119-125.
51. Cano-Contreras AD, Rascón O, Amieva-Balmori M, Ríos-Gálvez S, Maza YJ, Meixueiro-Daza A, Roesch-Dietlen F, et al. Approach, attitudes, and knowledge of general practitioners in relation to Helicobacter pylori is inadequate. There is much room for improvement! Rev Gastroenterol Mex (Engl Ed). 2018;83:16-24. doi:10.1016/j.rgmx.2017.02.004.
52. Misra V, Pandey R, Misra SP, Dwivedi M. Helicobacter pylori and gastric cancer: Indian enigma. World J Gastroenterol. 2014;20:1503-1509. doi:10.3748/wjg.v20.i6.1503
53. Lamont JT. Patient education: Helicobacter pylori infection and treatment (Beyond the Basics).[Online] 2020 Available at https://www.uptodate.com/contents/helicobacter-pylori-infection-and-treatment-beyond-the-basics#:~:text=pylori%20treatment%20usually%20includes%20several,help%20the%20ulcer%20to%20heal.&text=Most%20people%20are%20cured%20after%20finishing%20two%20weeks%20of%20medicine. Last accessed 28 June 22
54. Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, Moshiree B. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021;116:17-44. doi: 10.14309/ajg.0000000000001036.
55. Rahman MM, Mahadeva S, Ghoshal UC. Epidemiological and clinical perspectives on irritable bowel syndrome in India, Bangladesh and Malaysia: A review. World J Gastroenterol. 2017;23:6788-6801. doi: 10.3748/wjg.v23.i37.6788.
56. Halpert AD. Importance of early diagnosis in patients with irritable bowel syndrome. Postgrad Med. 2010;122:102-111. doi:10.3810/pgm.2010.03.2127.
57. Card TR, Siffledeen J, Fleming KM. Are IBD patients more likely to have a prior diagnosis of irritable bowel syndrome? Report of a case-control study in the General Practice Research Database. United European Gastroenterol J. 2014;2:505-512. doi:10.1177/2050640614554217
58. Hungin AP, Molloy-Bland M, Claes R, Heidelbaugh J, Cayley WE Jr, Muris J, et al. Systematic review: the perceptions, diagnosis and management of irritable bowel syndrome in primary care--a Rome Foundation working team report. Aliment Pharmacol Ther. 2014;40:1133-1145. doi:10.1111/apt.12957.
59. Quigley EM. Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye?. Therap Adv Gastroenterol. 2016;9:199-212. doi:10.1177/1756283X15621230.
60. Lacy BE. An Individualized, Case-Based Approach to the Management of Irritable Bowel Syndrome. J Fam Pract. 2020;69(7 Suppl):S8-S13.
61. Szałwińska P, Włodarczyk J, Spinelli A, Fichna J, Włodarczyk M. IBS-Symptoms in IBD Patients-Manifestation of Concomitant or Different Entities. J Clin Med. 2020;10:31. doi:10.3390/jcm10010031.
62. Stanisic V, Quigley EM. The overlap between IBS and IBD: what is it and what does it mean?. Expert Rev Gastroenterol Hepatol. 2014;8:139-145. doi:10.1586/17474124.2014.876361.
63. Cozma-Petruţ A, Loghin F, Miere D, Dumitraşcu DL. Diet in irritable bowel syndrome: What to recommend, not what to forbid to patients!. World J Gastroenterol. 2017;23:3771-3783. doi:10.3748/wjg.v23.i21.3771
64. Hungin APS, Mitchell CR, Whorwell P, Mulligan C, Cole O, Agréus L, et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensus. Aliment Pharmacol Ther. 2018;47:1054-1070. doi:10.1111/apt.14539
65. Rej A, Avery A, Ford AC, Holdoway A, Kurien M, McKenzie Y, et al. Clinical application of dietary therapies in irritable bowel syndrome. J Gastrointestin Liver Dis. 2018;27:307-316. doi:10.15403/jgld.2014.1121.273.avy
66. Shapiro JM, Subedi S, LeLeiko NS. Inflammatory Bowel Disease. Pediatr Rev. 2016;37:337-347. doi: 10.1542/pir.2015-0110. Erratum in: Pediatr Rev. 2016 Sep;37(9):405.
67. Kedia S, Ahuja V. Epidemiology of Inflammatory Bowel Disease in India: The Great Shift East. Inflamm Intest Dis. 2017;2:102-115. doi: 10.1159/000465522.
68. Das K, Ghoshal UC, Dhali GK, Benjamin J, Ahuja V, Makharia GK. Crohn's disease in India: a multicenter study from a country where tuberculosis is endemic. Dig Dis Sci. 2009;54:1099-1107. doi: 10.1007/s10620-008-0469-6.
69. Ahuja V, Tandon RK. Inflammatory bowel disease in the Asia-Pacific area: a comparison with developed countries and regional differences. J Dig Dis. 2010;11:134-47. doi: 10.1111/j.1751-2980.2010.00429.x.
70. Sood A, Kaur K, Mahajan R, Midha V, Singh A, Sharma S, et al. Colitis and Crohn's Foundation (India): a first nationwide inflammatory bowel disease registry. Intest Res. 2021;19:206-216. doi: 10.5217/ir.2019.09169.
71. Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015;21:1982-1992. doi:10.1097/MIB.0000000000000392.
72. Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life. 2019;12:113-122. doi:10.25122/jml-2018-0075.
73. Borg-Bartolo SP, Boyapati RK, Satsangi J, Kalla R. Precision medicine in inflammatory bowel disease: concept, progress and challenges. F1000Res. 2020;9:F1000 Faculty Rev-54. doi:10.12688/f1000research.20928.1.
74. Sairenji T, Collins KL, Evans DV. An Update on Inflammatory Bowel Disease. Prim Care. 2017;44:673-692. doi:10.1016/j.pop.2017.07.010.
75. Morrison G, Headon B, Gibson P. Update in inflammatory bowel disease. Aust Fam Physician. 2009;38:956-961.
76. Prasad SS, Potter M, Keely S, Talley NJ, Walker MM, Kairuz T. Roles of healthcare professionals in the management of chronic gastrointestinal diseases with a focus on primary care: A systematic review. JGH Open. 2019;4:221-229. doi:10.1002/jgh3.12235.
77. Afzali A, Armuzzi A, Bouhnik Y, Bressler B, Hart A, Rubin D, et al. P393 Patient and physician perspectives on the management of inflammatory bowel disease: Role of steroids in the context of biologic therapy. J Crohn's Colitis. 2020;14(Supplement_1):S366-S7. doi/10.1093/ecco-jcc/jjz203.522
78. Orlicka K, Barnes E, Culver EL. Prevention of infection caused by immunosuppressive drugs in gastroenterology. Ther Adv Chronic Dis. 2013;4:167-185. doi:10.1177/2040622313485275
79. Włodarczyk J, Waśniewska A, Fichna J, Dziki A, Dziki Ł, Włodarczyk M. Current Overview on Clinical Management of Chronic Constipation. J Clin Med. 2021;10:1738. doi:10.3390/jcm10081738.
80. Daniali M, Nikfar S, Abdollahi M. An overview of interventions for constipation in adults. Expert Rev Gastroenterol Hepatol. 2020;14:721-732. doi:10.1080/17474124.2020.1781617.
81. Bharucha AE. Constipation. Best Pract Res Clin Gastroenterol. 2007;21:709-731. doi:10.1016/j.bpg.2007.07.001.
82. Forootan M, Bagheri N, Darvishi M. Chronic constipation: A review of literature. Medicine (Baltimore). 2018;97:e10631. doi:10.1097/MD.0000000000010631.
83. Makharia GK, Verma AK, Amarchand R, Goswami A, Singh P, Agnihotri A, et al. Prevalence of irritable bowel syndrome: a community based study from northern India. J Neurogastroenterol Motil. 2011;17:82-87. doi:10.5056/jnm.2011.17.1.82.
84. Ghoshal UC, Abraham P, Bhatt C, Choudhuri G, Bhatia SJ, Shenoy KT, et al. Epidemiological and clinical profile of irritable bowel syndrome in India: report of the Indian Society of Gastroenterology Task Force. Indian J Gastroenterol. 2008;27:22-28..
85. Rajput M, Saini SK. Prevalence of constipation among the general population: a community-based survey from India. Gastroenterol Nurs. 2014;37:425–429. doi: 10.1097/SGA.0000000000000074.
86. Kasthuri A, Hegde SKB, Joseph MA. Prevalence of constipation among elderly in a rural area of Bangalore. IJRRMS. 2013;3:1
87. Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:1582–1591. doi: 10.1038/ajg.2011.164.
88. Ghoshal UC, Sachdeva S, Pratap N, Verma A, Karyampudi A, Misra A, et al. Indian consensus on chronic constipation in adults: A joint position statement of the Indian Motility and Functional Diseases Association and the Indian Society of Gastroenterology. Indian J Gastroenterol. 2018;37:526-544. doi:10.1007/s12664-018-0894-1
89. Scott SM, Simrén M, Farmer AD, Dinning PG, Carrington EV, Benninga MA, et al. Corsetti M. Chronic constipation in adults: Contemporary perspectives and clinical challenges. 1: Epidemiology, diagnosis, clinical associations, pathophysiology and investigation. Neurogastroenterol Motil. 2021;33:e14050. doi: 10.1111/nmo.14050.
90. Ray G. Evaluation of the Symptom of Constipation in Indian Patients. J Clin Diagn Res. 2016;10:OC01-OC3. doi:10.7860/JCDR/2016/15487.7524.
91. Makharia GK, Verma AK, Amarchand R, Bhatnagar S, Das P, Goswami A, et al. Prevalence of celiac disease in the northern part of India: a community based study. J Gastroenterol Hepatol. 2011;26:894-900. doi: 10.1111/j.1440-1746.2010.06606.x.
92. Goddard CJ, Gillett HR. Complications of coeliac disease: are all patients at risk?. Postgrad Med J. 2006;82:705-712. doi:10.1136/pgmj.2006.048876
93. Hahn M, Hagel AF, Hirschmann S, Bechthold C, Konturek P, Neurath M, et al. Modern diagnosis of celiac disease and relevant differential diagnoses in the case of cereal intolerance. Allergo J Int. 2014;23:67-77. doi:10.1007/s40629-014-0006-4
94. Ianiro G, Bibbò S, Bruno G, Ricci R, Arena V, Gasbarrini A, et al. Prior Misdiagnosis of Celiac Disease Is Common Among Patients Referred to a Tertiary Care Center: A Prospective Cohort Study. Clin Transl Gastroenterol. 2016;7:e139. doi:10.1038/ctg.2015.48.
95. Khurana V, Chico G. Undiagnosed celiac disease: a risk factor for cancer: a case series: 195. Official J Am Coll Gastroenterol. 2004;99.
96. Kelly CP, Bai JC, Liu E, Leffler DA. Advances in diagnosis and management of celiac disease. Gastroenterology. 2015;148:1175-1186. doi:10.1053/j.gastro.2015.01.044
97. National cancer registry programme, Indian council of medical research (ICMR), Bangalore, India (2013) Three-year report of the population based cancer registries- 2009-2011. Available at https://main.icmr.nic.in/sites/default/files/reports/Preliminary_Pages_Printed.pdf Last accessed 19-Oct-2022.
98. Consensus Document For Management Of Colorectal Cancer. Prepared as an outcome of ICMR Subcommittee on Colorectal Cancer. Available at https://main.icmr.nic.in/sites/default/files/guidelines/Colorectal%20Cancer_0.pdf Last accessed 19-Oct-2022
99. Patil PS, Saklani A, Gambhire P, Mehta S, Engineer R, De'Souza A, Chopra S, Bal M. Colorectal Cancer in India: An Audit from a Tertiary Center in a Low Prevalence Area. Indian J Surg Oncol. 2017;8:484-490. doi: 10.1007/s13193-017-0655-0.
100. Kulkarni V, Darshan BB, Unnikrishnan B, et al. Colorectal Cancer: How Familiar Are Our Future Doctors with the Cancer of Tomorrow?. Biomed Res Int. 2018;2018:7462101. doi:10.1155/2018/7462101.
101. Xirasagar S, Hurley TG, Sros L, Hebert JR. Quality and safety of screening colonoscopies performed by primary care physicians with standby specialist support. Med Care. 2010;48:703-709. doi:10.1097/MLR.0b013e3181e358a3.
102. Servarayan Murugesan C, Manickavasagam K, Chandramohan A, Jebaraj A, Jameel ARA, Jain MS, Venkataraman J. Gastric cancer in India: epidemiology and standard of treatment. Updates Surg. 2018;70:233-239. doi: 10.1007/s13304-018-0527-3.
103. Hanks H, Veitch C, Harris M. Colorectal cancer management - the role of the GP. Aust Fam Physician. 2008;37:259-261.
104. Triantafillidis JK, Vagianos C, Gikas A, Korontzi M, Papalois A. Screening for colorectal cancer: the role of the primary care physician. Eur J Gastroenterol Hepatol. 2017;29:e1-e7. doi:10.1097/MEG.0000000000000759).
105. Scheid DC, Hamm RM, Ramakrishnan K, McCarthy LH, Mold JW; Oklahoma Physicians Resource/Research Network. Improving colorectal cancer screening in family medicine: an Oklahoma Physicians Resource/Research Network (OKPRN) study. J Am Board Fam Med. 2013;26:498-507. doi:10.3122/jabfm.2013.05.120230
106. Edwards JK, Norris TE. Colonoscopy in rural communities: can family physicians perform the procedure with safe and efficacious results?. J Am Board Fam Pract. 2004;17:353-358. doi:10.3122/jabfm.17.5.353.
107. Wilkins T, LeClair B, Smolkin M, et al. Screening colonoscopies by primary care physicians: a meta-analysis. Ann Fam Med. 2009;7:56-62. doi:10.1370/afm.939.
108. Azzopardi J, DeWitt DE. Quality and safety issues in procedural rural practice: a prospective evaluation of current quality and safety guidelines in 3000 colonoscopies. Rural Remote Health. 2012;12:1949.
109. Kolber MR, Wong CK, Fedorak RN, Rowe BH; APC-Endo Study Physicians. Prospective Study of the Quality of Colonoscopies Performed by Primary Care Physicians: The Alberta Primary Care Endoscopy (APC-Endo) Study. PLoS One. 2013;8:e67017. doi:10.1371/journal.pone.0067017
110. Logan EC, Yates JM, Stewart RM, Fielding K, Kendrick D. Investigation and management of iron deficiency anaemia in general practice: a cluster randomised controlled trial of a simple management prompt. Postgrad Med J. 2002;78:533-537. doi:10.1136/pmj.78.923.533.
111. Droogendijk J, Beukers R, Berendes PB, Tax MG, Sonneveld P, Levin MD. Screening for gastrointestinal malignancy in patients with iron deficiency anemia by general practitioners: an observational study. Scand J Gastroenterol. 2011;46:1105-1110. doi:10.3109/00365521.2011.594082.
112. Pasechnikov V, Chukov S, Fedorov E, Kikuste I, Leja M. Gastric cancer: prevention, screening and early diagnosis. World J Gastroenterol. 2014;20:13842-13862. doi:10.3748/wjg.v20.i38.13842.
113. Ryan J, Murkies A. Diagnosis of upper gastrointestinal malignancy. Aust Fam Physician. 2006;35:200-201.
114. Ko CW, Siddique SM, Patel A, Harris A, Sultan S, Altayar O, et al. AGA Clinical Practice Guidelines on the Gastrointestinal Evaluation of Iron Deficiency Anemia. Gastroenterology. 2020;159:1085-1094. doi:10.1053/j.gastro.2020.06.046
115. Bramble MG, Suvakovic Z, Hungin AP. Detection of upper gastrointestinal cancer in patients taking antisecretory therapy prior to gastroscopy. Gut. 2000;46:464-467. doi:10.1136/gut.46.4.464.
116. Panter SJ, O'Flanagan H, Bramble MG, Hungin AP. Empirical use of antisecretory drug therapy delays diagnosis of upper gastrointestinal adenocarcinoma but does not effect outcome. Aliment Pharmacol Ther. 2004;19:981-988. doi:10.1111/j.1365-2036.2004.01924.x.
117. Wayman J, Hayes N, Raimes SA, Griffin SM. Prescription of proton pump inhibitors before endoscopy. A potential cause of missed diagnosis of early gastric cancers. Arch Fam Med. 2000;9:385-388. doi:10.1001/archfami.9.4.385.
118. Witzig R, Schönberger B, Fink U, Busch R, Gundel H, Sendler A, et al. Delays in diagnosis and therapy of gastric cancer and esophageal adenocarcinoma. Endoscopy. 2006;38:1122-1126. doi:10.1055/s-2006-944847.
119. Subasinghe D, Samarasekera DN. Delay in the diagnosis of esophageal carcinoma: experience of a single unit from a developing country. Indian J Cancer. 2010;47:151-155. doi:10.4103/0019-509X.63009.
120. Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin. 2002;52:195-215. doi:10.3322/canjclin.52.4.195.
121. di Pietro M, Fitzgerald RC; BSG Barrett's guidelines working group. Revised British Society of Gastroenterology recommendation on the diagnosis and management of Barrett's oesophagus with low-grade dysplasia. Gut. 2018;67:392-393. doi:10.1136/gutjnl-2017-314135
122. Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang JY, Watson P, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut. 2014;63:7-42. doi:10.1136/gutjnl-2013-305372
123. Samarasam I. Esophageal cancer in India: Current status and future perspectives. Int J Adv Med Health Res 2017;4:5-10. DOI: 10.4103/IJAMR.IJAMR_19_17
124. Satsangi S, Chawla YK. Viral hepatitis: Indian scenario. Med J Armed Forces India. 2016;72:204-210. doi: 10.1016/j.mjafi.2016.06.011.
125. Rakesh PS, Mainu TTCR, Raj A, Babu D, Rajiv M, Mohandas KS, et al. Investigating a community wide outbreak of hepatitis A in Kerala, India. J Family Med Prim Care. 2018;7:1537-1541. doi:10.4103/jfmpc.jfmpc_127_18.
126. Arankalle V, Mitra M, Bhave S, Ghosh A, Balasubramanian S, Chatterjee S, Choudhury J, Chitkara A, Kadhe G, Mane A, Roy S. Changing epidemiology of hepatitis A virus in Indian children. Vaccine: Development and Therapy. 2014;4:7-13.https://doi.org/10.2147/VDT.S53324.
127. Tomar BS. Hepatitis E in India. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1998;39:150-156.
128. Aggarwal R, Jameel S. Hepatitis E. Hepatology. 2011;54(6):2218-2226. doi:10.1002/hep.24674.
129. Acharya SK, Madan K, Dattagupta S, Panda SK. Viral hepatitis in India. Natl Med J India. 2006;19:203-217.
130. Devarbhavi H. Drug-Induced Liver Injury Unique to India. Clin Liver Dis (Hoboken). 2021;18:108-110. doi:10.1002/cld.1120.
131. Amarapurkar D, Dharod M, Amarapurkar A. Autoimmune hepatitis in India: single tertiary referral centre experience. Trop Gastroenterol. 2015;36:36-45. doi:10.7869/tg.243.
132. Investigation of Acute Non-Viral Hepatitis of Unknown Etiology Potentially Associated with an Alkaline Water Product: Center for Disease Control and Prevention; 2021 Available from: https://www.cdc.gov/nceh/hsb/chemicals/nonviralhepatitis.htm Last accessed 10-May-2022
133. European Association for the Study of the Liver. Electronic address: [email protected]; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370-398. doi:10.1016/j.jhep.2017.03.021.
134. Bonnemain CL, Cochand L, Portmann A, Béguelin C. Nouveaux aspects de la prise en charge de l’hépatite D [Recent advances in managing hepatitis D]. Rev Med Suisse. 2019;15:1802-1806..
135. Lok AS. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S303-S309. doi:10.1053/j.gastro.2004.09.045.
136. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 Suppl 1):S35-S50. doi:10.1053/j.gastro.2004.09.014.
137. Colombo M, Lleo A. The impact of antiviral therapy on hepatocellular carcinoma epidemiology. Hepat Oncol. 2018;5(1):HEP03. doi:10.2217/hep-2017-0024.
138. Elsayes KM, Chernyak V, Morshid AI, Tang A, Kielar AZ, Bashir MR, et al. Spectrum of Pitfalls, Pseudolesions, and Potential Misdiagnoses in Cirrhosis Am J Roentgenol. 2018;211:87-96. doi:10.2214/AJR.18.19781.
139. Gill US, Zissimopoulos A, Al-Shamma S, Burke K, McPhail MJ, Barr DA et al. Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk?. J Infect Dis. 2015;211:374-382. doi:10.1093/infdis/jiu471.
140. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ. 2005;172:367-379. doi:10.1503/cmaj.1040752.
141. Schaefer TJ, John S. Acute Hepatitis. [Updated 2022 Jul 18]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551570/ Last Accessed 22-Oct-2022
142. Kwong S, Meyerson C, Zheng W, Kassardjian A, Stanzione N, Zhang K, et al. Acute hepatitis and acute liver failure: Pathologic diagnosis and differential diagnosis. Semin Diagn Pathol. 2019;36:404-414. doi:10.1053/j.semdp.2019.07.005.
143. Lefkowitch JH. Morphology of alcoholic liver disease. Clin Liver Dis. 2005;9:37-53. doi:10.1016/j.cld.2004.11.001.
144. Guindi M. Wilson disease. Semin Diagn Pathol. 2019;36(6):415-422. doi:10.1053/j.semdp.2019.07.008.
145. Lewis J. Pathological patterns of biliary disease. Clin Liver Dis (Hoboken). 2017;10:107-110. doi:10.1002/cld.667.
146. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84. doi:10.1002/hep.28431.
147. Huang DQ, El-Serag HB, Loomba R. Global Epidemiology of NAFLD-Related HCC: Trends, Predictions, Risk Factors and Prevention. Nat Rev Gastroenterol Hepatol.2021;18:223–38. doi: 10.1038/s41575-020-00381-6
148. Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018;68:349-360. doi:10.1002/hep.29721
149. Ajmera V, Loomba R. Imaging Biomarkers of NAFLD, NASH, and Fibrosis. Mol Metab.2021; 50:101167. doi: 10.1016/j.molmet.2021.101167
150. Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol 2017; 23: 8263-8276. DOI: http://dx.doi. org/10.3748/wjg.v23.i47.8263
151. Golabi P, Sayiner M, Fazel Y, Koenig A, Henry L, Younossi ZM. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis. Expert Rev Gastroenterol Hepatol. 2016;10:63-71. doi: 10.1586/17474124.2016.1099433.
152. Duseja A, Singh SP, Saraswat VA, Acharya SK, Chawla YK, Chowdhury S, et al. Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. J Clin Exp Hepatol. 2015;5:51-68. doi:10.1016/j.jceh.2015.02.006.
153. Duseja A, Najmy S, Sachdev S, Pal A, Sharma RR, Marwah N, et al. High prevalence of non-alcoholic fatty liver disease among healthy male blood donors of urban India. JGH Open. 2019;3:133-139. doi:10.1002/jgh3.12117.
154. Asadullah M, Shivashankar R, Shalimar, Kandasamy D, Kondal D, Rautela G, Peerzada A, et al. Rural-Urban differentials in prevalence, spectrum and determinants of Non-alcoholic Fatty Liver Disease in North Indian population. PLoS One. 2022;17:e0263768. doi:10.1371/journal.pone.0263768.
155. Mahajan R, Duseja A, Kumar R, Chakraborti A, Lakshmi PV. A community-based study to determine the prevalence of nonalcoholic fatty liver disease (NAFLD) and its metabolic risk factors in urban and rural communities of north India. J Gastroenterol Hepatol 2019;34(suppl 3):310.
156. Cleveland E, Bandy A, VanWagner LB. Diagnostic challenges of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Clin Liver Dis (Hoboken). 2018;11:98-104. doi:10.1002/cld.716.
157. Filozof C, Goldstein BJ, Williams RN, Sanyal A. Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway. Drugs. 2015;75:1373-1392. doi:10.1007/s40265-015-0437-3.
158. Patel AM, Yeola M, Mahakalkar C. Demographic and Risk Factor Profile in Patients of Gallstone Disease in Central India. Cureus. 2022;14:e24993. doi:10.7759/cureus.24993.
159. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898-1906. doi:10.1053/j.gastro.2005.03.084.
160. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328-357. doi:10.1002/hep.29367.
161. Guidelines for the Treatment of Gallstones. Ann Intern Med. 1993;119:620-2. https://doi.org/10.7326/0003-4819-119-7_Part_1-199310010-00011
162. Gyedu A, Adae-Aboagye K, Badu-Peprah A. Prevalence of cholelithiasis among persons undergoing abdominal ultrasound at the Komfo Anokye Teaching Hospital, Kumasi, Ghana. Afr Health Sci. 2015;15:246-252. doi:10.4314/ahs.v15i1.32.
163. Almond S, Mant D, Thompson M. Diagnostic safety-netting. Br J Gen Pract. 2009;59:872-874. doi:10.3399/bjgp09X472971.
164. Castrejón M, Chew KW, Javanbakht M, Humphries R, Saab S, Klausner JD. Implementation of a Large System-Wide Hepatitis C Virus Screening and Linkage to Care Program for Baby Boomers. Open Forum Infect Dis. 2017;4:ofx109. doi:10.1093/ofid/ofx109
165. Konerman MA, Thomson M, Gray K, Moore M, Choxi H, Seif E, et al. Impact of an electronic health record alert in primary care on increasing hepatitis c screening and curative treatment for baby boomers. Hepatology. 2017;66:1805-1813. doi:10.1002/hep.29362
2. Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD. Hepatology. 2020;72:1605-1616. doi: 10.1002/hep.31173.
3. Shah D, Makharia GK, Ghoshal UC, Varma S, Ahuja V, Hutfless S. Burden of gastrointestinal and liver diseases in India, 1990-2016. Indian J Gastroenterol. 2018;37:439-445. doi: 10.1007/s12664-018-0892-3.
4. PAHO. The burden of digestive diseases in the Region of the Americas, 2000-2019. Pan American Health Organization. 2021. Available at https://www.paho.org/en/noncommunicable-diseases-and-mental-health/noncommunicable-diseases-and-mental-health-data-38 Last accessed 03-Oct-2022
5. Jones R. Primary care research and clinical practice: gastroenterology. Postgrad Med J. 2008;84:454-458.
6. Salvi S, Apte K, Madas S, Barne M, Chhowala S, Sethi T, et al. Symptoms and medical conditions in 204 912 patients visiting primary health-care practitioners in India: a 1-day point prevalence study (the POSEIDON study). Lancet Glob Health. 2015;3:e776-784. doi: 10.1016/S2214-109X(15)00152-7.
7. Committee on Diagnostic Error in Health Care; Board on Health Care Services; Institute of Medicine; The National Academies of Sciences, Engineering, and Medicine; Balogh EP, Miller BT, Ball JR, editors. Improving Diagnosis in Health Care. Washington (DC): National Academies Press (US); 2015 Dec 29. 3, Overview of Diagnostic Error in Health Care. Available at: https://www.ncbi.nlm.nih.gov/books/NBK338594/ Last accessed 03-Oct-2022
8. Kostopoulou O, Delaney BC, Munro CW. Diagnostic difficulty and error in primary care--a systematic review. Fam Pract. 2008;25:400-413.
9. Harada T, Watari T, Watanuki S, Hiroshige J, Kushiro S, Miyagami T, et al. Diagnostic error rates and associated factors for lower gastrointestinal perforation. Sci Rep. 2022;12:1028. doi: 10.1038/s41598-021-04762-y.
10. Sriram S, Khan MM. Effect of health insurance program for the poor on out-of-pocket inpatient care cost in India: evidence from a nationally representative cross-sectional survey. BMC Health Serv Res. 2020;20(1):839. doi:10.1186/s12913-020-05692-7
11. Diagnostic Errors: Technical Series on Safer Primary Care. Geneva: World Health Organization; 2016. Licence: CC BY-NC-SA 3.0 IGO. Accessed at https://apps.who.int/iris/bitstream/handle/10665/252410/9789241511636-eng.pdf on 03-Oct-2022
12. Norström F, Lindholm L, Sandström O, Nordyke K, Ivarsson A. Delay to celiac disease diagnosis and its implications for health-related quality of life. BMC Gastroenterol. 2011;11:118. doi:10.1186/1471-230X-11-118
13. Mehta S. GI cancers may masquerade as digestive disorders: Times of India; 2019 [Available from: https://timesofindia.indiatimes.com/city/visakhapatnam/gi-cancers-may-masquerade-as-digestive-disorders-docs/articleshow/69528231.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst. 03-Oct-2022
14. Vaezi MF. Atypical manifestations of gastroesophageal reflux disease. MedGenMed. 2005;7:25.
15. Fujiwara Y, Arakawa T. Overlap in patients with dyspepsia/functional dyspepsia. J Neurogastroenterol Motil. 2014;20:447-457. doi:10.5056/jnm14080.
16. Norström F, Lindholm L, Sandström O, Nordyke K, Ivarsson A. Delay to celiac disease diagnosis and its implications for health-related quality of life. BMC Gastroenterol. 2011;11:118. doi:10.1186/1471-230X-11-118
17. Timmermans WM, van Laar JA, van Hagen PM, van Zelm MC. Immunopathogenesis of granulomas in chronic autoinflammatory diseases. Clin Transl Immunology. 2016;5:e118. doi:10.1038/cti.2016.75
18. Sathoo S, Nachiappan DS, Sureshkumar S, Anandhi A. A qualitative exploratory study of delay in the presentation of gastrointestinal cancer. J Family Med Prim Care. 2021;10):278-282. doi:10.4103/jfmpc.jfmpc_1283_20
19. Bhatia SJ, Makharia GK, Abraham P, et al. Indian consensus on gastroesophageal reflux disease in adults: A position statement of the Indian Society of Gastroenterology. Indian J Gastroenterol. 2019;38:411-440. doi:10.1007/s12664-019-00979-y
20. Rai S, Kulkarni A, Ghoshal UC. Prevalence and risk factors for gastroesophageal reflux disease in the Indian population: A meta-analysis and meta-regression study. Indian J Gastroenterol. 2021;40:209-219. doi: 10.1007/s12664-020-01104-0.
21. Sandhu DS, Fass R. Current Trends in the Management of Gastroesophageal Reflux Disease. Gut Liver. 2018;12:7-16. doi: 10.5009/gnl16615.
22. Smith J, Woodcock A, Houghton L. New developments in reflux-associated cough. Lung. 2010;188 Suppl 1:S81-S86. doi:10.1007/s00408-009-9210-2.
23. Woodcock A, Young EC, Smith JA. New insights in cough. Br Med Bull. 2010;96:61-73. doi:10.1093/bmb/ldq034
24. Bhatia SJ, Reddy DN, Ghoshal UC, Jayanthi V, Abraham P, Choudhuri G, et al. Epidemiology and symptom profile of gastroesophageal reflux in the Indian population: report of the Indian Society of Gastroenterology Task Force. Indian J Gastroenterol. 2011;30:118-127. doi:10.1007/s12664-011-0112-x.
25. Smith JA, Decalmer S, Kelsall A, McGuinness K, Jones H, Galloway S, et al. Acoustic cough-reflux associations in chronic cough: potential triggers and mechanisms. Gastroenterology. 2010;139:754-762. doi:10.1053/j.gastro.2010.06.050.
26. Jain M. Evaluation of noncardiac chest pain in Indian setting--can we reduce the investigation burden?. Indian J Gastroenterol. 2015;34:266-267. doi:10.1007/s12664-014-0527-2
27. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308-329. doi:10.1038/ajg.2012.444.
28. Kahrilas PJ, Smith JA, Dicpinigaitis PV. A causal relationship between cough and gastroesophageal reflux disease (GERD) has been established: a pro/con debate. Lung. 2014;192:39-46. doi:10.1007/s00408-013-9528-7.
29. Pore R, Biswas S, Das S. Prevailing Practices for the Management of Dry Cough in India: A Questionnaire Based Survey. J Assoc Physicians India. 2016;64:48-54.
30. Bhatia S, Pareek KK, Kumar A, Upadhyay R, Tiwaskar M, Jain A, et al. API-ISG Consensus Guidelines for Management of Gastrooesophageal Reflux Disease. J Assoc Physicians India. 2020;68:69-80.
31. Fass R, Ofman JJ. Gastroesophageal reflux disease--should we adopt a new conceptual framework? Am J Gastroenterol. 2002;97:1901-1909. doi:10.1111/j.1572-0241.2002.05912.x
32. Jung DH, Park H. Is Gastroesophageal Reflux Disease and Achalasia Coincident or Not? J Neurogastroenterol Motil. 2017;23:5-8. doi: 10.5056/jnm16121.
33. Kessing BF, Bredenoord AJ, Smout AJ. Erroneous diagnosis of gastroesophageal reflux disease in achalasia. Clin Gastroenterol Hepatol. 2011;9:1020-1024. doi:10.1016/j.cgh.2011.04.022
34. Fallone CA, Guyatt GH, Armstrong D, et al. Do physicians correctly assess patient symptom severity in gastro-oesophageal reflux disease?. Aliment Pharmacol Ther. 2004;20:1161-1169. doi:10.1111/j.1365-2036.2004.02257.x.
35. McColl E, Junghard O, Wiklund I, Revicki DA. Assessing symptoms in gastroesophageal reflux disease: how well do clinicians' assessments agree with those of their patients?. Am J Gastroenterol. 2005;100:11-18. doi:10.1111/j.1572-0241.2005.40945.x
36. Flook NW, Wiklund I. Accounting for the effect of GERD symptoms on patients' health-related quality of life: supporting optimal disease management by primary care physicians. Int J Clin Pract. 2007;61:2071-2078. doi:10.1111/j.1742-1241.2007.01586.x
37. Ponce J, Garrigues V, Agréus L, Tabaglio E, Gschwantler M, Guallar E, et al. Structured management strategy based on the Gastro-oesophageal Reflux Disease (GERD) Questionnaire (GerdQ) vs. usual primary care for GERD: pooled analysis of five cluster-randomised European studies. Int J Clin Pract. 2012;66:897-905. doi:10.1111/j.1742-1241.2012.02992.x
38. Savarino V, Dulbecco P, de Bortoli N, Ottonello A, Savarino E. The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. Eur J Intern Med. 2017;37:19-24. doi:10.1016/j.ejim.2016.10.007
39. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ; American Gastroenterological Association. American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology. 2011;140:e18-e13. doi:10.1053/j.gastro.2011.01.031.
40. Johnson DA, Katz PO, Armstrong D, Cohen H, Delaney BC, Howden CW, et al. The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus. Drugs. 2017;77:547-561. doi:10.1007/s40265-017-0712-6.
41. Scarpignato C, Gatta L, Zullo A, Blandizzi C; SIF-AIGO-FIMMG Group; Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14:179. doi:10.1186/s12916-016-0718-z
42. Moayyedi P, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG Clinical Guideline: Management of Dyspepsia. Am J Gastroenterol. 2017;112:988-1013. doi: 10.1038/ajg.2017.154.
43. Barberio B, Mahadeva S, Black CJ, Savarino EV, Ford AC. Systematic review with meta-analysis: global prevalence of uninvestigated dyspepsia according to the Rome criteria. Aliment Pharmacol Ther. 2020;52:762-773. doi: 10.1111/apt.16006.
44. Mahadeva S, Goh KL. Epidemiology of functional dyspepsia: a global perspective. World J Gastroenterol. 2006;12:2661-2666.
45. Eusebi LH, Ratnakumaran R, Bazzoli F, Ford AC. Prevalence of Dyspepsia in Individuals With Gastroesophageal Reflux-Type Symptoms in the Community: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018;16:39-48.e1. doi:10.1016/j.cgh.2017.07.041.
46. Nasseri-Moghaddam S, Mousavian AH, Kasaeian A, Kanno T, Yuan Y, Ford AC, et al. What is the Prevalence of Clinically Significant Endoscopic Findings in Subjects With Dyspepsia? Updated Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022;S1542-3565(22)00594-8. doi:10.1016/j.cgh.2022.05.041.
47. Plummer M, Franceschi S, Vignat J, Forman D, de Martel C. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer. 2015;136:487-490. doi:10.1002/ijc.28999
48. Vakil N. Dyspepsia, peptic ulcer, and H. pylori: a remembrance of things past. Am J Gastroenterol. 2010;105:572-574. doi:10.1038/ajg.2009.709
49. Wu Y, Su T, Zhou X, Lu N, Li Z, Du Y. Awareness and attitudes regarding Helicobacter pylori infection in Chinese physicians and public population: A national cross-sectional survey. Helicobacter. 2020;25:e12705. doi:10.1111/hel.12705.
50. Mansour Ghanaei1 F, Joukar F, Soati F, Gharib S. Knowledge and Practice of General Practitioners and Internists about Helicobacter pylori infection in Guilan, Iran. Middle East J Dig Dis. 2011;3:119-125.
51. Cano-Contreras AD, Rascón O, Amieva-Balmori M, Ríos-Gálvez S, Maza YJ, Meixueiro-Daza A, Roesch-Dietlen F, et al. Approach, attitudes, and knowledge of general practitioners in relation to Helicobacter pylori is inadequate. There is much room for improvement! Rev Gastroenterol Mex (Engl Ed). 2018;83:16-24. doi:10.1016/j.rgmx.2017.02.004.
52. Misra V, Pandey R, Misra SP, Dwivedi M. Helicobacter pylori and gastric cancer: Indian enigma. World J Gastroenterol. 2014;20:1503-1509. doi:10.3748/wjg.v20.i6.1503
53. Lamont JT. Patient education: Helicobacter pylori infection and treatment (Beyond the Basics).[Online] 2020 Available at https://www.uptodate.com/contents/helicobacter-pylori-infection-and-treatment-beyond-the-basics#:~:text=pylori%20treatment%20usually%20includes%20several,help%20the%20ulcer%20to%20heal.&text=Most%20people%20are%20cured%20after%20finishing%20two%20weeks%20of%20medicine. Last accessed 28 June 22
54. Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, Moshiree B. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021;116:17-44. doi: 10.14309/ajg.0000000000001036.
55. Rahman MM, Mahadeva S, Ghoshal UC. Epidemiological and clinical perspectives on irritable bowel syndrome in India, Bangladesh and Malaysia: A review. World J Gastroenterol. 2017;23:6788-6801. doi: 10.3748/wjg.v23.i37.6788.
56. Halpert AD. Importance of early diagnosis in patients with irritable bowel syndrome. Postgrad Med. 2010;122:102-111. doi:10.3810/pgm.2010.03.2127.
57. Card TR, Siffledeen J, Fleming KM. Are IBD patients more likely to have a prior diagnosis of irritable bowel syndrome? Report of a case-control study in the General Practice Research Database. United European Gastroenterol J. 2014;2:505-512. doi:10.1177/2050640614554217
58. Hungin AP, Molloy-Bland M, Claes R, Heidelbaugh J, Cayley WE Jr, Muris J, et al. Systematic review: the perceptions, diagnosis and management of irritable bowel syndrome in primary care--a Rome Foundation working team report. Aliment Pharmacol Ther. 2014;40:1133-1145. doi:10.1111/apt.12957.
59. Quigley EM. Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye?. Therap Adv Gastroenterol. 2016;9:199-212. doi:10.1177/1756283X15621230.
60. Lacy BE. An Individualized, Case-Based Approach to the Management of Irritable Bowel Syndrome. J Fam Pract. 2020;69(7 Suppl):S8-S13.
61. Szałwińska P, Włodarczyk J, Spinelli A, Fichna J, Włodarczyk M. IBS-Symptoms in IBD Patients-Manifestation of Concomitant or Different Entities. J Clin Med. 2020;10:31. doi:10.3390/jcm10010031.
62. Stanisic V, Quigley EM. The overlap between IBS and IBD: what is it and what does it mean?. Expert Rev Gastroenterol Hepatol. 2014;8:139-145. doi:10.1586/17474124.2014.876361.
63. Cozma-Petruţ A, Loghin F, Miere D, Dumitraşcu DL. Diet in irritable bowel syndrome: What to recommend, not what to forbid to patients!. World J Gastroenterol. 2017;23:3771-3783. doi:10.3748/wjg.v23.i21.3771
64. Hungin APS, Mitchell CR, Whorwell P, Mulligan C, Cole O, Agréus L, et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensus. Aliment Pharmacol Ther. 2018;47:1054-1070. doi:10.1111/apt.14539
65. Rej A, Avery A, Ford AC, Holdoway A, Kurien M, McKenzie Y, et al. Clinical application of dietary therapies in irritable bowel syndrome. J Gastrointestin Liver Dis. 2018;27:307-316. doi:10.15403/jgld.2014.1121.273.avy
66. Shapiro JM, Subedi S, LeLeiko NS. Inflammatory Bowel Disease. Pediatr Rev. 2016;37:337-347. doi: 10.1542/pir.2015-0110. Erratum in: Pediatr Rev. 2016 Sep;37(9):405.
67. Kedia S, Ahuja V. Epidemiology of Inflammatory Bowel Disease in India: The Great Shift East. Inflamm Intest Dis. 2017;2:102-115. doi: 10.1159/000465522.
68. Das K, Ghoshal UC, Dhali GK, Benjamin J, Ahuja V, Makharia GK. Crohn's disease in India: a multicenter study from a country where tuberculosis is endemic. Dig Dis Sci. 2009;54:1099-1107. doi: 10.1007/s10620-008-0469-6.
69. Ahuja V, Tandon RK. Inflammatory bowel disease in the Asia-Pacific area: a comparison with developed countries and regional differences. J Dig Dis. 2010;11:134-47. doi: 10.1111/j.1751-2980.2010.00429.x.
70. Sood A, Kaur K, Mahajan R, Midha V, Singh A, Sharma S, et al. Colitis and Crohn's Foundation (India): a first nationwide inflammatory bowel disease registry. Intest Res. 2021;19:206-216. doi: 10.5217/ir.2019.09169.
71. Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015;21:1982-1992. doi:10.1097/MIB.0000000000000392.
72. Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life. 2019;12:113-122. doi:10.25122/jml-2018-0075.
73. Borg-Bartolo SP, Boyapati RK, Satsangi J, Kalla R. Precision medicine in inflammatory bowel disease: concept, progress and challenges. F1000Res. 2020;9:F1000 Faculty Rev-54. doi:10.12688/f1000research.20928.1.
74. Sairenji T, Collins KL, Evans DV. An Update on Inflammatory Bowel Disease. Prim Care. 2017;44:673-692. doi:10.1016/j.pop.2017.07.010.
75. Morrison G, Headon B, Gibson P. Update in inflammatory bowel disease. Aust Fam Physician. 2009;38:956-961.
76. Prasad SS, Potter M, Keely S, Talley NJ, Walker MM, Kairuz T. Roles of healthcare professionals in the management of chronic gastrointestinal diseases with a focus on primary care: A systematic review. JGH Open. 2019;4:221-229. doi:10.1002/jgh3.12235.
77. Afzali A, Armuzzi A, Bouhnik Y, Bressler B, Hart A, Rubin D, et al. P393 Patient and physician perspectives on the management of inflammatory bowel disease: Role of steroids in the context of biologic therapy. J Crohn's Colitis. 2020;14(Supplement_1):S366-S7. doi/10.1093/ecco-jcc/jjz203.522
78. Orlicka K, Barnes E, Culver EL. Prevention of infection caused by immunosuppressive drugs in gastroenterology. Ther Adv Chronic Dis. 2013;4:167-185. doi:10.1177/2040622313485275
79. Włodarczyk J, Waśniewska A, Fichna J, Dziki A, Dziki Ł, Włodarczyk M. Current Overview on Clinical Management of Chronic Constipation. J Clin Med. 2021;10:1738. doi:10.3390/jcm10081738.
80. Daniali M, Nikfar S, Abdollahi M. An overview of interventions for constipation in adults. Expert Rev Gastroenterol Hepatol. 2020;14:721-732. doi:10.1080/17474124.2020.1781617.
81. Bharucha AE. Constipation. Best Pract Res Clin Gastroenterol. 2007;21:709-731. doi:10.1016/j.bpg.2007.07.001.
82. Forootan M, Bagheri N, Darvishi M. Chronic constipation: A review of literature. Medicine (Baltimore). 2018;97:e10631. doi:10.1097/MD.0000000000010631.
83. Makharia GK, Verma AK, Amarchand R, Goswami A, Singh P, Agnihotri A, et al. Prevalence of irritable bowel syndrome: a community based study from northern India. J Neurogastroenterol Motil. 2011;17:82-87. doi:10.5056/jnm.2011.17.1.82.
84. Ghoshal UC, Abraham P, Bhatt C, Choudhuri G, Bhatia SJ, Shenoy KT, et al. Epidemiological and clinical profile of irritable bowel syndrome in India: report of the Indian Society of Gastroenterology Task Force. Indian J Gastroenterol. 2008;27:22-28..
85. Rajput M, Saini SK. Prevalence of constipation among the general population: a community-based survey from India. Gastroenterol Nurs. 2014;37:425–429. doi: 10.1097/SGA.0000000000000074.
86. Kasthuri A, Hegde SKB, Joseph MA. Prevalence of constipation among elderly in a rural area of Bangalore. IJRRMS. 2013;3:1
87. Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:1582–1591. doi: 10.1038/ajg.2011.164.
88. Ghoshal UC, Sachdeva S, Pratap N, Verma A, Karyampudi A, Misra A, et al. Indian consensus on chronic constipation in adults: A joint position statement of the Indian Motility and Functional Diseases Association and the Indian Society of Gastroenterology. Indian J Gastroenterol. 2018;37:526-544. doi:10.1007/s12664-018-0894-1
89. Scott SM, Simrén M, Farmer AD, Dinning PG, Carrington EV, Benninga MA, et al. Corsetti M. Chronic constipation in adults: Contemporary perspectives and clinical challenges. 1: Epidemiology, diagnosis, clinical associations, pathophysiology and investigation. Neurogastroenterol Motil. 2021;33:e14050. doi: 10.1111/nmo.14050.
90. Ray G. Evaluation of the Symptom of Constipation in Indian Patients. J Clin Diagn Res. 2016;10:OC01-OC3. doi:10.7860/JCDR/2016/15487.7524.
91. Makharia GK, Verma AK, Amarchand R, Bhatnagar S, Das P, Goswami A, et al. Prevalence of celiac disease in the northern part of India: a community based study. J Gastroenterol Hepatol. 2011;26:894-900. doi: 10.1111/j.1440-1746.2010.06606.x.
92. Goddard CJ, Gillett HR. Complications of coeliac disease: are all patients at risk?. Postgrad Med J. 2006;82:705-712. doi:10.1136/pgmj.2006.048876
93. Hahn M, Hagel AF, Hirschmann S, Bechthold C, Konturek P, Neurath M, et al. Modern diagnosis of celiac disease and relevant differential diagnoses in the case of cereal intolerance. Allergo J Int. 2014;23:67-77. doi:10.1007/s40629-014-0006-4
94. Ianiro G, Bibbò S, Bruno G, Ricci R, Arena V, Gasbarrini A, et al. Prior Misdiagnosis of Celiac Disease Is Common Among Patients Referred to a Tertiary Care Center: A Prospective Cohort Study. Clin Transl Gastroenterol. 2016;7:e139. doi:10.1038/ctg.2015.48.
95. Khurana V, Chico G. Undiagnosed celiac disease: a risk factor for cancer: a case series: 195. Official J Am Coll Gastroenterol. 2004;99.
96. Kelly CP, Bai JC, Liu E, Leffler DA. Advances in diagnosis and management of celiac disease. Gastroenterology. 2015;148:1175-1186. doi:10.1053/j.gastro.2015.01.044
97. National cancer registry programme, Indian council of medical research (ICMR), Bangalore, India (2013) Three-year report of the population based cancer registries- 2009-2011. Available at https://main.icmr.nic.in/sites/default/files/reports/Preliminary_Pages_Printed.pdf Last accessed 19-Oct-2022.
98. Consensus Document For Management Of Colorectal Cancer. Prepared as an outcome of ICMR Subcommittee on Colorectal Cancer. Available at https://main.icmr.nic.in/sites/default/files/guidelines/Colorectal%20Cancer_0.pdf Last accessed 19-Oct-2022
99. Patil PS, Saklani A, Gambhire P, Mehta S, Engineer R, De'Souza A, Chopra S, Bal M. Colorectal Cancer in India: An Audit from a Tertiary Center in a Low Prevalence Area. Indian J Surg Oncol. 2017;8:484-490. doi: 10.1007/s13193-017-0655-0.
100. Kulkarni V, Darshan BB, Unnikrishnan B, et al. Colorectal Cancer: How Familiar Are Our Future Doctors with the Cancer of Tomorrow?. Biomed Res Int. 2018;2018:7462101. doi:10.1155/2018/7462101.
101. Xirasagar S, Hurley TG, Sros L, Hebert JR. Quality and safety of screening colonoscopies performed by primary care physicians with standby specialist support. Med Care. 2010;48:703-709. doi:10.1097/MLR.0b013e3181e358a3.
102. Servarayan Murugesan C, Manickavasagam K, Chandramohan A, Jebaraj A, Jameel ARA, Jain MS, Venkataraman J. Gastric cancer in India: epidemiology and standard of treatment. Updates Surg. 2018;70:233-239. doi: 10.1007/s13304-018-0527-3.
103. Hanks H, Veitch C, Harris M. Colorectal cancer management - the role of the GP. Aust Fam Physician. 2008;37:259-261.
104. Triantafillidis JK, Vagianos C, Gikas A, Korontzi M, Papalois A. Screening for colorectal cancer: the role of the primary care physician. Eur J Gastroenterol Hepatol. 2017;29:e1-e7. doi:10.1097/MEG.0000000000000759).
105. Scheid DC, Hamm RM, Ramakrishnan K, McCarthy LH, Mold JW; Oklahoma Physicians Resource/Research Network. Improving colorectal cancer screening in family medicine: an Oklahoma Physicians Resource/Research Network (OKPRN) study. J Am Board Fam Med. 2013;26:498-507. doi:10.3122/jabfm.2013.05.120230
106. Edwards JK, Norris TE. Colonoscopy in rural communities: can family physicians perform the procedure with safe and efficacious results?. J Am Board Fam Pract. 2004;17:353-358. doi:10.3122/jabfm.17.5.353.
107. Wilkins T, LeClair B, Smolkin M, et al. Screening colonoscopies by primary care physicians: a meta-analysis. Ann Fam Med. 2009;7:56-62. doi:10.1370/afm.939.
108. Azzopardi J, DeWitt DE. Quality and safety issues in procedural rural practice: a prospective evaluation of current quality and safety guidelines in 3000 colonoscopies. Rural Remote Health. 2012;12:1949.
109. Kolber MR, Wong CK, Fedorak RN, Rowe BH; APC-Endo Study Physicians. Prospective Study of the Quality of Colonoscopies Performed by Primary Care Physicians: The Alberta Primary Care Endoscopy (APC-Endo) Study. PLoS One. 2013;8:e67017. doi:10.1371/journal.pone.0067017
110. Logan EC, Yates JM, Stewart RM, Fielding K, Kendrick D. Investigation and management of iron deficiency anaemia in general practice: a cluster randomised controlled trial of a simple management prompt. Postgrad Med J. 2002;78:533-537. doi:10.1136/pmj.78.923.533.
111. Droogendijk J, Beukers R, Berendes PB, Tax MG, Sonneveld P, Levin MD. Screening for gastrointestinal malignancy in patients with iron deficiency anemia by general practitioners: an observational study. Scand J Gastroenterol. 2011;46:1105-1110. doi:10.3109/00365521.2011.594082.
112. Pasechnikov V, Chukov S, Fedorov E, Kikuste I, Leja M. Gastric cancer: prevention, screening and early diagnosis. World J Gastroenterol. 2014;20:13842-13862. doi:10.3748/wjg.v20.i38.13842.
113. Ryan J, Murkies A. Diagnosis of upper gastrointestinal malignancy. Aust Fam Physician. 2006;35:200-201.
114. Ko CW, Siddique SM, Patel A, Harris A, Sultan S, Altayar O, et al. AGA Clinical Practice Guidelines on the Gastrointestinal Evaluation of Iron Deficiency Anemia. Gastroenterology. 2020;159:1085-1094. doi:10.1053/j.gastro.2020.06.046
115. Bramble MG, Suvakovic Z, Hungin AP. Detection of upper gastrointestinal cancer in patients taking antisecretory therapy prior to gastroscopy. Gut. 2000;46:464-467. doi:10.1136/gut.46.4.464.
116. Panter SJ, O'Flanagan H, Bramble MG, Hungin AP. Empirical use of antisecretory drug therapy delays diagnosis of upper gastrointestinal adenocarcinoma but does not effect outcome. Aliment Pharmacol Ther. 2004;19:981-988. doi:10.1111/j.1365-2036.2004.01924.x.
117. Wayman J, Hayes N, Raimes SA, Griffin SM. Prescription of proton pump inhibitors before endoscopy. A potential cause of missed diagnosis of early gastric cancers. Arch Fam Med. 2000;9:385-388. doi:10.1001/archfami.9.4.385.
118. Witzig R, Schönberger B, Fink U, Busch R, Gundel H, Sendler A, et al. Delays in diagnosis and therapy of gastric cancer and esophageal adenocarcinoma. Endoscopy. 2006;38:1122-1126. doi:10.1055/s-2006-944847.
119. Subasinghe D, Samarasekera DN. Delay in the diagnosis of esophageal carcinoma: experience of a single unit from a developing country. Indian J Cancer. 2010;47:151-155. doi:10.4103/0019-509X.63009.
120. Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin. 2002;52:195-215. doi:10.3322/canjclin.52.4.195.
121. di Pietro M, Fitzgerald RC; BSG Barrett's guidelines working group. Revised British Society of Gastroenterology recommendation on the diagnosis and management of Barrett's oesophagus with low-grade dysplasia. Gut. 2018;67:392-393. doi:10.1136/gutjnl-2017-314135
122. Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang JY, Watson P, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut. 2014;63:7-42. doi:10.1136/gutjnl-2013-305372
123. Samarasam I. Esophageal cancer in India: Current status and future perspectives. Int J Adv Med Health Res 2017;4:5-10. DOI: 10.4103/IJAMR.IJAMR_19_17
124. Satsangi S, Chawla YK. Viral hepatitis: Indian scenario. Med J Armed Forces India. 2016;72:204-210. doi: 10.1016/j.mjafi.2016.06.011.
125. Rakesh PS, Mainu TTCR, Raj A, Babu D, Rajiv M, Mohandas KS, et al. Investigating a community wide outbreak of hepatitis A in Kerala, India. J Family Med Prim Care. 2018;7:1537-1541. doi:10.4103/jfmpc.jfmpc_127_18.
126. Arankalle V, Mitra M, Bhave S, Ghosh A, Balasubramanian S, Chatterjee S, Choudhury J, Chitkara A, Kadhe G, Mane A, Roy S. Changing epidemiology of hepatitis A virus in Indian children. Vaccine: Development and Therapy. 2014;4:7-13.https://doi.org/10.2147/VDT.S53324.
127. Tomar BS. Hepatitis E in India. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1998;39:150-156.
128. Aggarwal R, Jameel S. Hepatitis E. Hepatology. 2011;54(6):2218-2226. doi:10.1002/hep.24674.
129. Acharya SK, Madan K, Dattagupta S, Panda SK. Viral hepatitis in India. Natl Med J India. 2006;19:203-217.
130. Devarbhavi H. Drug-Induced Liver Injury Unique to India. Clin Liver Dis (Hoboken). 2021;18:108-110. doi:10.1002/cld.1120.
131. Amarapurkar D, Dharod M, Amarapurkar A. Autoimmune hepatitis in India: single tertiary referral centre experience. Trop Gastroenterol. 2015;36:36-45. doi:10.7869/tg.243.
132. Investigation of Acute Non-Viral Hepatitis of Unknown Etiology Potentially Associated with an Alkaline Water Product: Center for Disease Control and Prevention; 2021 Available from: https://www.cdc.gov/nceh/hsb/chemicals/nonviralhepatitis.htm Last accessed 10-May-2022
133. European Association for the Study of the Liver. Electronic address: [email protected]; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370-398. doi:10.1016/j.jhep.2017.03.021.
134. Bonnemain CL, Cochand L, Portmann A, Béguelin C. Nouveaux aspects de la prise en charge de l’hépatite D [Recent advances in managing hepatitis D]. Rev Med Suisse. 2019;15:1802-1806..
135. Lok AS. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S303-S309. doi:10.1053/j.gastro.2004.09.045.
136. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 Suppl 1):S35-S50. doi:10.1053/j.gastro.2004.09.014.
137. Colombo M, Lleo A. The impact of antiviral therapy on hepatocellular carcinoma epidemiology. Hepat Oncol. 2018;5(1):HEP03. doi:10.2217/hep-2017-0024.
138. Elsayes KM, Chernyak V, Morshid AI, Tang A, Kielar AZ, Bashir MR, et al. Spectrum of Pitfalls, Pseudolesions, and Potential Misdiagnoses in Cirrhosis Am J Roentgenol. 2018;211:87-96. doi:10.2214/AJR.18.19781.
139. Gill US, Zissimopoulos A, Al-Shamma S, Burke K, McPhail MJ, Barr DA et al. Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk?. J Infect Dis. 2015;211:374-382. doi:10.1093/infdis/jiu471.
140. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ. 2005;172:367-379. doi:10.1503/cmaj.1040752.
141. Schaefer TJ, John S. Acute Hepatitis. [Updated 2022 Jul 18]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551570/ Last Accessed 22-Oct-2022
142. Kwong S, Meyerson C, Zheng W, Kassardjian A, Stanzione N, Zhang K, et al. Acute hepatitis and acute liver failure: Pathologic diagnosis and differential diagnosis. Semin Diagn Pathol. 2019;36:404-414. doi:10.1053/j.semdp.2019.07.005.
143. Lefkowitch JH. Morphology of alcoholic liver disease. Clin Liver Dis. 2005;9:37-53. doi:10.1016/j.cld.2004.11.001.
144. Guindi M. Wilson disease. Semin Diagn Pathol. 2019;36(6):415-422. doi:10.1053/j.semdp.2019.07.008.
145. Lewis J. Pathological patterns of biliary disease. Clin Liver Dis (Hoboken). 2017;10:107-110. doi:10.1002/cld.667.
146. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84. doi:10.1002/hep.28431.
147. Huang DQ, El-Serag HB, Loomba R. Global Epidemiology of NAFLD-Related HCC: Trends, Predictions, Risk Factors and Prevention. Nat Rev Gastroenterol Hepatol.2021;18:223–38. doi: 10.1038/s41575-020-00381-6
148. Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018;68:349-360. doi:10.1002/hep.29721
149. Ajmera V, Loomba R. Imaging Biomarkers of NAFLD, NASH, and Fibrosis. Mol Metab.2021; 50:101167. doi: 10.1016/j.molmet.2021.101167
150. Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol 2017; 23: 8263-8276. DOI: http://dx.doi. org/10.3748/wjg.v23.i47.8263
151. Golabi P, Sayiner M, Fazel Y, Koenig A, Henry L, Younossi ZM. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis. Expert Rev Gastroenterol Hepatol. 2016;10:63-71. doi: 10.1586/17474124.2016.1099433.
152. Duseja A, Singh SP, Saraswat VA, Acharya SK, Chawla YK, Chowdhury S, et al. Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. J Clin Exp Hepatol. 2015;5:51-68. doi:10.1016/j.jceh.2015.02.006.
153. Duseja A, Najmy S, Sachdev S, Pal A, Sharma RR, Marwah N, et al. High prevalence of non-alcoholic fatty liver disease among healthy male blood donors of urban India. JGH Open. 2019;3:133-139. doi:10.1002/jgh3.12117.
154. Asadullah M, Shivashankar R, Shalimar, Kandasamy D, Kondal D, Rautela G, Peerzada A, et al. Rural-Urban differentials in prevalence, spectrum and determinants of Non-alcoholic Fatty Liver Disease in North Indian population. PLoS One. 2022;17:e0263768. doi:10.1371/journal.pone.0263768.
155. Mahajan R, Duseja A, Kumar R, Chakraborti A, Lakshmi PV. A community-based study to determine the prevalence of nonalcoholic fatty liver disease (NAFLD) and its metabolic risk factors in urban and rural communities of north India. J Gastroenterol Hepatol 2019;34(suppl 3):310.
156. Cleveland E, Bandy A, VanWagner LB. Diagnostic challenges of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Clin Liver Dis (Hoboken). 2018;11:98-104. doi:10.1002/cld.716.
157. Filozof C, Goldstein BJ, Williams RN, Sanyal A. Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway. Drugs. 2015;75:1373-1392. doi:10.1007/s40265-015-0437-3.
158. Patel AM, Yeola M, Mahakalkar C. Demographic and Risk Factor Profile in Patients of Gallstone Disease in Central India. Cureus. 2022;14:e24993. doi:10.7759/cureus.24993.
159. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898-1906. doi:10.1053/j.gastro.2005.03.084.
160. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328-357. doi:10.1002/hep.29367.
161. Guidelines for the Treatment of Gallstones. Ann Intern Med. 1993;119:620-2. https://doi.org/10.7326/0003-4819-119-7_Part_1-199310010-00011
162. Gyedu A, Adae-Aboagye K, Badu-Peprah A. Prevalence of cholelithiasis among persons undergoing abdominal ultrasound at the Komfo Anokye Teaching Hospital, Kumasi, Ghana. Afr Health Sci. 2015;15:246-252. doi:10.4314/ahs.v15i1.32.
163. Almond S, Mant D, Thompson M. Diagnostic safety-netting. Br J Gen Pract. 2009;59:872-874. doi:10.3399/bjgp09X472971.
164. Castrejón M, Chew KW, Javanbakht M, Humphries R, Saab S, Klausner JD. Implementation of a Large System-Wide Hepatitis C Virus Screening and Linkage to Care Program for Baby Boomers. Open Forum Infect Dis. 2017;4:ofx109. doi:10.1093/ofid/ofx109
165. Konerman MA, Thomson M, Gray K, Moore M, Choxi H, Seif E, et al. Impact of an electronic health record alert in primary care on increasing hepatitis c screening and curative treatment for baby boomers. Hepatology. 2017;66:1805-1813. doi:10.1002/hep.29362